<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03388515</url>
  </required_header>
  <id_info>
    <org_study_id>SSS11</org_study_id>
    <nct_id>NCT03388515</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects.</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Single-dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSS11 Administered Intravenously in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Sunshine Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Sunshine Pharmaceutical Co., LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SSS11 is pegsiticase consisting of a recombinant uricase conjugated to multiple 20kDa PEG
      molecules. The purpose of this study is to assess the safety, tolerability, pharmacokinetics
      and pharmacodynamics of single dose SSS11 administered intravenously in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      Primary:

      • To assess the safety, tolerability of single dose SSS11 in healthy subjects

      Secondary:

      • To assess the pharmacokinetics, pharmacodynamics and immunogenicity of SSS-11 in healthy
      subjects

      Enrollment and Number of Arms (planned):

      40 subjects will be assigned into 5 dosing cohorts (1.5, 3, 6, 12 and 24mg) with 5-10
      subjects each.

      Original primary outcome Measures:

      Safety: Physical exam，ECG，Clinical laboratory tests，AE，SAE Tolerance assessment：MDT，DLT

      Original secondary outcome Measures:

      pharmacokinetics: Cmax, Tmax, AUC, CL, Vd, t1/2 pharmacodynamics: level of serum uric acid
      Immunogenicity ：anti-SSS11, anti-uricase and anti-PEG antibodies
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of adverse events</measure>
    <time_frame>baseline to 4 weeks</time_frame>
    <description>incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum tolerable dose</measure>
    <time_frame>baseline to 4 weeks</time_frame>
    <description>maximum tolerable dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>peak plasma concentration</measure>
    <time_frame>baseline to 4 weeks</time_frame>
    <description>peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the plasma concentration versus time curve</measure>
    <time_frame>baseline to 4 weeks</time_frame>
    <description>area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of serum uric acid</measure>
    <time_frame>baseline to 4 weeks</time_frame>
    <description>level of serum uric acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>baseline to 52 weeks</time_frame>
    <description>anti-SSS11</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>SSS11, 1.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSS11, 1.5mg, iv, single dose at Day 1;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSS11, 3.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSS11, 3.0mg, iv, single dose at Day 1;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSS11, 6.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSS11, 6.0mg, iv, single dose at Day 1;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSS11, 12.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSS11, 12.0mg, iv, single dose at Day 1;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSS11, 24.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSS11, 24.0mg, iv, single dose at Day 1;</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SSS11</intervention_name>
    <description>IV infusion for 60 min.</description>
    <arm_group_label>SSS11, 1.5mg</arm_group_label>
    <arm_group_label>SSS11, 3.0mg</arm_group_label>
    <arm_group_label>SSS11, 6.0mg</arm_group_label>
    <arm_group_label>SSS11, 12.0mg</arm_group_label>
    <arm_group_label>SSS11, 24.0mg</arm_group_label>
    <other_name>pegsiticase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>IV infusion for 60 min.</description>
    <arm_group_label>SSS11, 1.5mg</arm_group_label>
    <arm_group_label>SSS11, 3.0mg</arm_group_label>
    <arm_group_label>SSS11, 6.0mg</arm_group_label>
    <arm_group_label>SSS11, 12.0mg</arm_group_label>
    <arm_group_label>SSS11, 24.0mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Males and females, 18-45 years of age at time of consent; 2. Subjects are in good
        health, without any clinical significant symptoms or laboratory test; 3. Having a body mass
        index between 19 and 28 kilogram per meter square (kg/m²); 4. Capable of giving written
        informed consent 5. Understanding and being willing to comply with the requirements of
        protocol, participate to complete the study; 6. Having recovered if received a surgery
        before . Exclusion criteria：

          1. Allergic condition or having the history of allergic reactions to any drugs, pegylated
             products, or more than two substances;

          2. Use of any medicine within 4 weeks or shorter than 5 half-lives;

          3. Use of any medicine within 12 weeks, which is harm to any organ;

          4. Participated in any other clinical trial within 12 weeks;

          5. History of blood donation within 12 weeks;

          6. History of glucose-6-phosphate dehydrogenase deficiency;

          7. History of catalase deficiency;

          8. Any significant disease, including but not limited to the following: digestive system,
             cardiovascular system, respiratory system, urinary system, musculoskeletal system,
             endocrine system, neuropsychiatry system, hematological system, immune system,
             metabolic system abnormity.

          9. Abnormal significance clinical laboratory tests within 2 weeks such as routine blood
             test and urinalysis, blood chemistry, ECG.

         10. Positive serology for hepatitis B surface antigen , or antibodies to hepatitis C, or
             HIV and syphilis;

         11. Pregnancy, planning pregnancy, or breastfeeding;

         12. Positive pregnancy test;

         13. Male subject without effective contraception or his partner intend to be pregnant
             within 6 months;

         14. History of mental disorder or disabilities legally;

         15. History of alcohol abusing during the last 6 months;

         16. More than 5 cigarettes per day during the last 6 months;

         17. Positive drug abuse or alcohol test;

         18. More than 1L of strong tea, coffee or caffeine drink per day;

         19. Can't understand the content of informed consent form ;

         20. Any condition, which investigators consider, is not fit for the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianzhong Shentu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affilicated Hospital Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quanrui Wu, Master</last_name>
    <phone>13601126093</phone>
    <email>wuquanrui@3sbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affilicated Hospital Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian zhong Shen tu, Doctor</last_name>
      <phone>0571-87236560</phone>
      <email>stjz@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jian zhong Shen tu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>December 24, 2017</last_update_submitted>
  <last_update_submitted_qc>December 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

